Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2018 2
2019 4
2020 2
2021 4
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all
Page 1
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives.
Vernieri C, Milano M, Brambilla M, Mennitto A, Maggi C, Cona MS, Prisciandaro M, Fabbroni C, Celio L, Mariani G, Bianchi GV, Capri G, de Braud F. Vernieri C, et al. Among authors: cona ms. Crit Rev Oncol Hematol. 2019 Jul;139:53-66. doi: 10.1016/j.critrevonc.2019.05.001. Epub 2019 May 3. Crit Rev Oncol Hematol. 2019. PMID: 31112882 Review.
Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
Signorelli D, Macerelli M, Proto C, Vitali M, Cona MS, Agustoni F, Zilembo N, Platania M, Trama A, Gallucci R, Ganzinelli M, Pelosi G, Pastorino U, de Braud F, Garassino MC, Lo Russo G. Signorelli D, et al. Among authors: cona ms. Tumori. 2016 Jan-Feb;102(1):18-30. doi: 10.5301/tj.5000436. Epub 2015 Oct 14. Tumori. 2016. PMID: 26481865 Review.
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Signorelli D, Giannatempo P, Grazia G, Aiello MM, Bertolini F, Mirabile A, Buti S, Vasile E, Scotti V, Pisapia P, Cona MS, Rolfo C, Malapelle U; Immune-Oncology YOUNG Group. Signorelli D, et al. Among authors: cona ms. Biomed Res Int. 2019 Apr 24;2019:9056417. doi: 10.1155/2019/9056417. eCollection 2019. Biomed Res Int. 2019. PMID: 31179334 Free PMC article. Review.
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer.
Vernieri C, Prisciandaro M, Nichetti F, Lobefaro R, Peverelli G, Ligorio F, Zattarin E, Cona MS, Sepe P, Corti F, Manglaviti S, Brambilla M, Re B, Belfiore A, Pruneri G, Celio L, Mariani G, Bianchi GV, Rivoltini L, Capri G, de Braud F. Vernieri C, et al. Among authors: cona ms. Cancers (Basel). 2020 Mar 6;12(3):617. doi: 10.3390/cancers12030617. Cancers (Basel). 2020. PMID: 32155941 Free PMC article.
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles.
Vernieri C, Prisciandaro M, Milano M, Cona MS, Maggi C, Brambilla M, Mennitto A, Fabbroni C, Farè E, Cresta S, Celio L, Mariani G, Bianchi G, Capri G, de Braud F. Vernieri C, et al. Among authors: cona ms. Clin Breast Cancer. 2019 Apr;19(2):e306-e318. doi: 10.1016/j.clbc.2018.12.004. Epub 2018 Dec 12. Clin Breast Cancer. 2019. PMID: 30635175
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer.
Vernieri C, Mennitto A, Prisciandaro M, Huber V, Milano M, Rinaldi L, Cona MS, Maggi C, Ferrari B, Manoukian S, Mariani G, Bianchi G, Capri G, Rivoltini L, de Braud F. Vernieri C, et al. Among authors: cona ms. Sci Rep. 2018 Jun 7;8(1):8703. doi: 10.1038/s41598-018-27075-z. Sci Rep. 2018. PMID: 29880896 Free PMC article. Clinical Trial.
Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies.
Cona MS, Lecchi M, Cresta S, Damian S, Del Vecchio M, Necchi A, Poggi MM, Raggi D, Randon G, Ratta R, Signorelli D, Vernieri C, de Braud F, Verderio P, Di Nicola M. Cona MS, et al. Cancers (Basel). 2019 Feb 14;11(2):223. doi: 10.3390/cancers11020223. Cancers (Basel). 2019. PMID: 30769874 Free PMC article.
12 results